A review of the DTaP-IPV-HB-PRP-T Hexavalent vaccine in pediatric patients

Poliovirus is detected in sewage from north and east London

(2022) Jacqui Wise   BMJ-British Medical Journal

Hexavalent vaccines in infants: a systematic literature review and meta-analysis of the solicited local and systemic adverse reactions of two hexavalent vaccines

(2021) Piyali Mukherjee et al.   Expert Review of Vaccines

Vaccine-Related Errors in Reconstitution in South Korea: A National Physicians’ and Nurses’ Survey

(2021) Young Hwa Lee et al.   Vaccines

Hexavalent vaccines: What can we learn from head-to-head studies?

(2021) Markus Knuf et al.   VACCINE

Post-marketing surveillance study of the DTaP2-IPV-HB-Hib (Hexyon) vaccine administered in preterm infants in the Apulia region, Italy, in 2017

(2020) Domenico Martinelli et al.   VACCINE

Persistence of Hepatitis B Immune Memory Until 6 Years of Age Following Hexavalent DTaP-IPV-HB-PRP~T Vaccination in a 3-, 5- and 11- to 12-month Schedule and Response to a Subsequent Hepatitis B Challenge Vaccination

(2020) Miia Virta et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Immunogenicity and safety of a hexavalent pediatric vaccine in HIV-exposed infected and uninfected infants in Republic of South Africa

(2020) Anthonet Koen et al.   Human Vaccines & Immunotherapeutics

Knowledge and practices regarding infant vaccination: results of a survey of French physicians

(2019) Pierre Bakhache et al.   EUROPEAN JOURNAL OF PEDIATRICS

How Important Is the Type of Acellular Pertussis Vaccine?

(2019) Kathleen Harriman et al.   CLINICAL INFECTIOUS DISEASES

DTaP-IPV-HepB-Hib Vaccine (Hexyon®): An Updated Review of its Use in Primary and Booster Vaccination

(2019) Yahiya Y. Syed   PEDIATRIC DRUGS

Hexavalent vaccines: increasing options for policy-makers and providers. A review of the data supporting interchangeability (substitution with vaccines containing fewer antigens) and mixed schedules from the same manufacturer

(2018) Jan Dolhain et al.   Expert Review of Vaccines

Immunogenicity and Safety of Primary and Booster Vaccinations of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine in Healthy Infants and Toddlers in Germany and the Czech Republic

(2018) Roman Prymula et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Diphtheria vaccine: WHO position paper, August 2017 – Recommendations

(2018) World Health Organization   VACCINE

Persistence of hepatitis B immune memory until 9–10 years of age following hepatitis B vaccination at birth and DTaP-IPV-HB-PRP∼T vaccination at 2, 4 and 6 months

(2018) Pope Kosalaraksa et al.   Human Vaccines & Immunotherapeutics

Evaluation of a Hexavalent-Pentavalent-Hexavalent Infant Primary Vaccination Series Followed by a Pentavalent Booster Vaccine in Healthy Infants and Toddlers

(2018) Federico Martinón-Torres et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Concomitant administration of a fully liquid ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal ACWY conjugate vaccine in toddlers

(2018) Timo Vesikari et al.   VACCINE

Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration

(2018) Shabir A. Madhi et al.   Human Vaccines & Immunotherapeutics

A Randomized, Controlled Study of DTaP-IPV-HB-PRP-T, a Fully Liquid Hexavalent Vaccine, Administered in a 3-, 5- and 11- to 12-month Schedule

(2017) Timo Vesikari et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

A Randomized Controlled Study of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine for Primary and Booster Vaccinations of Healthy Infants and Toddlers in Latin America

(2017) Pío López et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

A fully liquid DTaP-IPV-HB-PRP-T hexavalent vaccine for primaryand booster vaccination of healthy Turkish infants and toddlers*

(2017) Mehmet CEYHAN et al.   Turkish Journal Of Medical Sciences

Immunogenicity and safety of a fully liquid DTaP-IPV-HB-PRP∼T hexavalent vaccine compared with the standard of care in infants in the Republic of Korea

(2017) Yun-Kyung Kim et al.   VACCINE

New perspectives for hexavalent vaccines

(2017) Pablo Obando-Pacheco et al.   VACCINE

Concomitant administration of a fully liquid, ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal serogroup C conjugate vaccine in infants

(2017) Timo Vesikari et al.   VACCINE

Current epidemiology of tetanus in England, 2001–2014

(2016) S. COLLINS et al.   EPIDEMIOLOGY AND INFECTION

Immunogenicity and safety of a liquid hexavalent vaccine in Indian infants

(2016) Jugesh Chhatwal et al.   INDIAN PEDIATRICS

Polio vaccination: past, present and future

(2015) Ananda S Bandyopadhyay et al.   Future Microbiology

Assessment of preparation time with fully-liquid versus non-fully liquid paediatric hexavalent vaccines. A time and motion study

(2015) Ilse De Coster et al.   VACCINE

Antibody Persistence and Booster Vaccination of a Fully Liquid Hexavalent Vaccine Co-Administered with Measles/Mumps/Rubella and Varicella Vaccines at 15-18 Months of Age in Healthy South African Infants

(2013) Shabir A. Madhi et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Safety and Immunogenicity of an Investigational Fully Liquid Hexavalent DTaP-IPV-Hep B-PRP-T Vaccine at Two, Four and Six Months of Age Compared With Licensed Vaccines in Latin America

(2012) Mercedes Macías et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

A fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Mexican children

(2012) Amalia Guadalupe Becerra Aquino et al.   VACCINE

Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules

(2011) Ray Borrow et al.   Expert Review of Vaccines

Immunogenicity and safety study of a new DTaP–IPV–Hep B–PRP-T combined vaccine compared to a licensed DTaP–IPV–Hep B//PRP-T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4, and 6 months of age in Thai infants

(2011) Pope Kosalaraksa et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Immunogenicity and Safety of an Investigational Hexavalent Diphtheria-tetanus-acellular Pertussis-inactivated Poliovirus-hepatitis B-Haemophilus influenzae B Conjugate Combined Vaccine in Healthy 2-, 4-, and 6-month-old Argentinean Infants

(2011) Miguel W. Tregnaghi et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Immunogenicity and Safety of an Investigational Fully Liquid Hexavalent Combination Vaccine Versus Licensed Combination Vaccines at 6, 10, and 14 Weeks of Age in Healthy South African Infants

(2011) Shabir A. Madhi et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Antibody Persistence After a Primary Series of a New DTaP-IPV-Hep B-PRP-T Combined Vaccine or Separate DTaP-IPV//PRP-T and Hepatitis B Vaccines at 2, 4, and 6 Months of Age and the Effect of a Subsequent DTaP-IPV//PRP-T Booster Vaccination at 18 Months of Age in Healthy Argentinean Infants

(2011) Marcelo Tregnaghi et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Correlates of Protection Induced by Vaccination

(2010) S. A. Plotkin   Clinical and Vaccine Immunology

Immunogenicity and safety of a novel yeast Hansenula polymorpha-derived recombinant Hepatitis B candidate vaccine in healthy adolescents and adults aged 10–45 years

(2010) Miguel W. Tregnaghi et al.   VACCINE